###begin article-title 0
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4</italic>
###xml 284 290 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 370 376 370 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 485 491 485 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 495 504 495 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
Peptidylarginine deiminase type 4 (PADI4) genotypes were shown to influence susceptibility to rheumatoid arthritis (RA) in the Japanese population. Such an association could not previously be confirmed in different European populations. In the present study, we analysed exons 2-4 of PADI4 in 102 German RA patients and 102 healthy individuals to study the influence of PADI4 variability on RA susceptibility by means of haplotype-specific DNA sequencing. Analyses of the influence of PADI4 and HLA-DRB1 genotypes on disease activity and on levels of anti-cyclic citrullinated peptide antibodies were performed.
###end p 2
###begin p 3
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 433 439 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 535 541 535 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 753 759 747 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 941 947 935 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 1185 1187 1179 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 647 655 <span type="species:ncbi:9606">patients</span>
###xml 863 871 <span type="species:ncbi:9606">patients</span>
Comparing the frequencies of PADI4 haplotype 4 (padi4_89*G, padi4_90*T, padi4_92*G, padi4_94*T, padi4_104*C, padi4_95*G, padi4_96*T) (patients, 14.7%; controls, 7.8%; odds ratio = 2.0, 95% confidence interval = 1.1-3.8) and carriers of this haplotype (patients, 27.5%; controls, 13.7%; odds ratio = 2.4, 95% confidence interval = 1.2-4.8), a significant positive association of PADI4 haplotype 4 with RA could be demonstrated. Other PADI4 haplotypes did not differ significantly between patients and controls. Regarding the individual PADI4 variants, padi4_89 (A-->G), padi4_90 (C-->T), and padi4_94 (C-->T) were significantly associated with RA (patients, 49.5%; controls, 38.7%; odds ratio = 1.6, 95% confidence interval = 1.1-2.3). Considering novel PADI4 variants located in or near to exons 2, 3, and 4, no quantitative or qualitative differences between RA patients (8.8%) and healthy controls (10.8%) could be demonstrated. While the PADI4 genotype did not influence disease activity and the anti-cyclic citrullinated peptide antibody level, the presence of the HLA-DRB1 shared epitope was significantly associated with higher anti-cyclic citrullinated peptide antibody levels (P = 0.033).
###end p 3
###begin p 4
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
The results of this small case-control study support the hypothesis that variability of the PADI4 gene may influence susceptibility to RA in the German population. Quantitative or qualitative differences in previously undefined PADI4 variants between patients and controls could not be demonstrated.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI1</italic>
###xml 225 231 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI6 </italic>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 396 397 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 573 574 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 757 758 757 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1070 1079 1070 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-vitro </italic>
###xml 1098 1099 1098 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1100 1101 1100 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Peptidylarginine deiminases (EC 3.5.3.15) are enzymes involved in the post-translational deimination of protein-bound arginine to citrulline [1]. Five different types of peptidylarginine deiminases encoded by the genes PADI1-PADI4 and PADI6 are currently known [1]. The presence of citrulline-modified target epitopes for autoantibodies is a well-known phenomenon in rheumatoid arthritis (RA) [2,3]. Peptidylarginine deiminases were recently implicated in the generation of anti-cyclic citrullinated peptide antibodies (anti-CCP) detectable in early stages of the disease [2-4]. The process resulting in anti-CCP formation is thought to play a pivotal role in early stages of RA evolvement since it is detectable several years before the onset of symptoms [5]. Certain evidence suggests that deimination of arginine at those peptide side-chain positions that interact with the so-called shared epitope of some major histocompatibility complex class II molecules (for example, HLA-DRB1*0401) may result in the generation of high-affinity peptides, thus inducing a strong in-vitro T cell activation [4,6].
###end p 6
###begin p 7
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI1</italic>
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4</italic>
###xml 169 170 169 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4</italic>
###xml 292 298 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 669 670 669 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 827 833 827 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 927 933 927 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 984 986 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1012 1018 1012 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 863 871 <span type="species:ncbi:9606">patients</span>
A Japanese research group recently identified a genomic region (1p36) containing the genes PADI1-PADI4, which were suspected to be associated with susceptibility to RA [7]. Peptidylarginine deiminase type 4 (PADI4) was identified as the gene actually responsible for the association with RA. PADI4 has at least five main haplotypes that differ at four exonic single nucleotide polymorphisms (SNPs) and three subsequent amino acid substitutions [7,8]. While the so-called susceptibility haplotypes 2, 3, and 4 were found to be significantly more frequent in Japanese individuals suffering from RA, the non-susceptibility haplotype 1 predominated in healthy individuals [7]. These results could be confirmed by a further Japanese study [9]. However, studies in different European countries did not reveal significantly different PADI4 haplotype distributions in RA patients and healthy individuals. Moreover, no influence of the PADI4 genotype on disease severity could be detected [10-14]. Thus, the relevance of PADI4 variability for susceptibility to RA is still unclear.
###end p 7
###begin p 8
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 551 557 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 689 695 689 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 734 740 734 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
A recent analysis of our group characterising exons 2-4 of the PADI4 gene identified new variants and haplotypes by a novel haplotype-specific sequencing-based approach [8]. Importantly, three novel coding SNPs in exons 2, 3, and 4 and three SNPs in introns 2 and 3 located near the exon-intron boundaries were found in 11/102 individuals (10.8%). Moreover, a closely related novel haplotype (haplotype 1B) was found in 2.9% of healthy individuals, which differs from haplotype 1 by padi4_92*G/padi4_96*C [8]. Since this additional variability of the PADI4 gene has not been assessed by other studies, the aim of the present case-control study was to investigate the possible influence of PADI4 genotypes including previously unknown PADI4 variants on susceptibility to RA in a German population.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
Subjects and clinical data
###end title 10
###begin p 11
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 242 248 242 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
Blood samples were obtained from 102 consecutive healthy, unrelated blood donors presenting in our institution as described previously [8]. These samples were analysed in our previous study for genetic variability of exons 2, 3, and 4 of the PADI4 gene [8]. Samples from 102 RA patients were enrolled to this study from the Department of Rheumatology, Charite Berlin and from the Rheumatology Unit, Ludwig Maximilian University, Munich. RA patients fulfilled the American College of Rheumatology criteria for RA [15]. The study was approved by the local ethics committee. All individuals were included in this study after informed consent was obtained.
###end p 11
###begin p 12
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 223 230 <span type="species:ncbi:9606">patient</span>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
###xml 474 479 <span type="species:ncbi:9606">women</span>
The median age at onset of RA was 47 years (range, 6-86 years). One of the patients (age at onset, six years; PADI4 haplotype constellation 1 + 2/3) presented with juvenile RA and later transformed to classical RA. Another patient (age at onset, 14 years; PADI4 haplotype constellation 2/3 + 2/3) presented with an early manifestation of classical RA. When excluding these two patients the median age at onset was 48 years (range, 17-86 years). Of the RA patients, 75% were women. The Disease Activity Score 28 was available in 77 cases (median, 5.2; range, 1.8-8.1). Anti-CCP antibodies were detectable in 47 of 75 cases (median, 100 U/ml; range, 0-1600 U/ml). The median age of the controls was 40 years (range, 19-64 years), and 58 (57%) were female.
###end p 12
###begin title 13
Haplotype-specific DNA amplification and DNA sequencing
###end title 13
###begin p 14
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 401 407 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 615 616 611 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
The extraction of genomic DNA, amplification, and cycle sequencing of exons 2-4 of PADI4 were performed as described previously [8]. Briefly, the respective PADI4 haplotypes were amplified using genomic DNA, primer pairs specific for PADI4 haplotype 1, haplotype 1B, haplotype 4, or haplotype 2/3, and Platinum PCR SuperMix High Fidelity (Invitrogen, Karlsruhe, Germany). In most cases the respective PADI4 haplotype constellations could be easily identified by gel electrophoretic separation of the amplification products (2% w/v agarose gel containing 0.1 microg/ml ethidium bromide) and UV visualisation (Figure 1).
###end p 14
###begin p 15
###xml 227 233 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 345 351 345 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 276 282 <span type="species:ncbi:8164">Suzuki</span>
After digestion of the remaining primers and dNTPs by ExoSAP-IT (Amersham Biosciences, Freiburg, Germany), the PCR products were sequenced. All primers were synthesised by TIB Molbiol (Berlin, Germany). The designations of the PADI4 haplotypes are in accordance with those of Suzuki and colleagues [7]. The positions of novel exonic or intronic PADI4 variants were designated relative to sequences NM_012387 and NT_034376.1, respectively.
###end p 15
###begin title 16
HLA-DRB1 genotyping, definition of the shared epitope, and anti-CCP measurement
###end title 16
###begin p 17
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 475 477 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 553 555 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
Sequencing-based high-resolution typing of HLA-DRB1 was performed in 58 cases using the Protrans S4 HLA-DRB1 kit (lot number 344A01; Protrans, Ketsch, Germany) as previously described [16]. Presence of the shared epitope was assessed in two ways. First, only HLA-DRB1*0401, HLA-DRB1*0404, and HLA-DRB1*0408 were considered. Second, the shared epitope was defined by all HLA-DRB1 alleles with the following constellations: DRss1 (67Leu-69Glu-71Lys or Arg-74Ala-86Gly or Val) [17]. Anti-CCP antibodies were measured in 75 cases using standard techniques [18].
###end p 17
###begin title 18
Statistical analysis
###end title 18
###begin p 19
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 271 280 271 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
Chi-square tests (odds ratio, 95% confidence interval) and Fisher's exact tests were performed using GraphPad Prism 4 (GraphPad Software, San Diego, CA, USA). Comparison of the serum anti-CCP levels and the Disease Activity Score 28 regarding dependence of the PADI4 and HLA-DRB1 genotypes was assessed by the Mann-Whitney U test (median and 25th-75th percentiles are presented).
###end p 19
###begin p 20
Chi-square testing for deviation from Hardy-Weinberg equilibrium was performed by a Java-based applet (Knud Christensen, Department of Animal and Veterinary Basic Sciences, Denmark; ).
###end p 20
###begin title 21
Results
###end title 21
###begin title 22
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
Distribution of PADI4 haplotype combinations
###end title 22
###begin p 23
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 159 165 159 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 431 437 431 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 616 622 616 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 720 722 720 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 786 792 786 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
###xml 739 747 <span type="species:ncbi:9606">patients</span>
The frequencies of the PADI4 haplotype combinations found in our study are presented in Table 1. A detailed description of the variability of exons 2-4 of the PADI4 gene in healthy individuals analysed by haplotype-specific DNA sequencing was given in our previous report [8]. PADI4 haplotype 1 was most frequently found in the homozygous form (34.3%) and in combination with haplotype 2/3 (34.3%) in normal controls. In contrast, PADI4 haplotype 1 occurred more frequently in combination with haplotype 2/3 (30.4%) than in the homozygous form (24.5%) in patients with RA. Most strikingly, the frequency of combined PADI4 haplotype 1/haplotype 4 was significantly different between patients (19.6%) and controls (8.8%) (P < 0.05). Both in patients and controls the distributions of the PADI4 haplotype combinations were in accordance with Hardy-Weinberg equilibrium.
###end p 23
###begin title 24
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
Frequencies of PADI4 haplotypes and carriers of PADI4 haplotypes
###end title 24
###begin p 25
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 219 221 219 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 415 417 415 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 440 446 440 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
When we compared the overall frequency of haplotype occurrence, haplotype 4 of PADI4 was significantly more prevalent in RA patients (14.7%) than in controls (7.8%) (odds ratio = 2.0, 95% confidence interval = 1.1-3.8, P = 0.04) (Table 2). The frequency of carriers of PADI4 haplotype 4 also differed significantly between patients (27.5%) and controls (13.7%) (odds ratio = 2.4, 95% confidence interval = 1.2-4.8, P = 0.02). For all other PADI4 haplotypes, there were no significant differences between patients and controls.
###end p 25
###begin title 26
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
Frequencies of PADI4 SNPs and novel PADI4 variants
###end title 26
###begin p 27
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 304 310 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 549 550 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 622 624 616 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
The haplotype-specific sequencing based approach used in this study covered the genomic regions of exons 2, 3, and 4 of PADI4 and included the SNPs padi4_89, padi4_90, padi4_92, padi4_94, padi4_104, padi4_95, and padi4_96. The approach used therefore allowed a very detailed analysis of this part of the PADI4 gene that was implicated in influencing RA susceptibility. Of these SNPs, the frequencies of padi4_89A-->G, padi4_90C-->T, and padi4_94C-->T in the RA patients (49.5%) were significantly different from those in the controls (38.7%) (Table 3). The resulting odds ratio was 1.6 (95% confidence interval = 1.1-2.3, P = 0.04).
###end p 27
###begin p 28
###xml 21 22 21 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 283 289 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 317 319 315 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 338 340 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 364 366 358 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 385 387 377 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 415 417 405 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 455 461 445 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 503 505 491 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 531 537 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
In an earlier study [8], six previously unknown PADI4 variants were discovered in 11 (10.8%) of the healthy controls included in the present study. Three of these resulted in amino acid substitutions. Nine (8.8%) of the RA patients from the present study exhibited five of these new PADI4 variants - 265G-->A (D89T) (n = 2), 390194C-->T (n = 1), 304C-->A (P102T) (n = 1), 393030A-->G (n = 1), and 392G-->C (R131T) (n = 3) - and another previously unknown PADI4 variant - 236C-->G (T79R), EMBL AJ966355 (n = 1). Comparison of these PADI4 variants did not reveal any significant quantitative or qualitative differences between patients and controls.
###end p 28
###begin title 29
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
Influence of PADI4 genotype on anti-CCP level and disease activity
###end title 29
###begin p 30
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 135 137 135 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 210 212 210 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 287 289 287 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 326 332 326 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 605 611 605 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 668 670 668 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 738 740 738 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 810 812 810 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
When comparing anti-CCP levels in carriers versus non-carriers of PADI4 haplotype 1 (median, 100 [0-437] U/ml versus 102 [0-644] U/ml; P = 0.69), haplotype 2/3 (median, 183 [0-651] U/ml versus 73 [0-200] U/ml; P = 0.13), and haplotype 4 (median, 71 [0-200] U/ml versus 183 [0-620] U/ml; P = 0.15), no significant influence of PADI4 genotype on anti-CCP level could be detected. Anti-CCP levels in PADI4 haplotype 1, haplotype 2/3, and haplotype 4 homozygotes were also not different. The disease activity measured by Disease Activity Score 28 differed non-significantly in carriers versus non-carriers of PADI4 haplotype 1 (median, 5.3 [4.3-6.3] versus 4.8 [3.5-5.7]; P = 0.17), haplotype 2/3 (median, 5.0 [3.9-5.9] versus 5.5 [4.6-6.4]; P = 0.23), and haplotype 4 (median, 5.2 [3.9-6.6] versus 5.2 [4.1-5.9]; P = 0.73).
###end p 30
###begin title 31
###xml 13 22 13 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
Influence of HLA-DRB1 genotype on anti-CCP level
###end title 31
###begin p 32
###xml 191 193 191 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 311 313 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The presence of the shared epitope, defined by the HLA-DRB1 alleles HLA-DRB1*0401, HLA-DRB1*0404, and HLA-DRB1*0408 (shared epitope present; median, 607 [17-1170] U/ml versus 0 [0-392] U/ml; P = 0.048) or by DRbeta1 (67Leu-69Glu-71Lys or Arg-74Ala-86Gly or Val; median, 607 [0-1170] U/ml versus 0 [0-252] U/ml; P = 0.033), significantly influenced the level of anti-CCP.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 250 256 250 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 503 509 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 652 658 652 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 755 761 755 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 1001 1007 1001 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 1091 1092 1091 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1204 1205 1204 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1206 1208 1206 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1209 1211 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1212 1214 1212 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
This study provides a hint that variability of the PADI4 gene is related to the susceptibility to RA in the German population, whereas certain differences of hitherto unknown PADI4 variants between patients and controls were not found. The impact of PADI4 genotypes on susceptibility to RA remains controversial [7,9-14]. Until now, certain PADI4 genotypes (haplotypes 2, 3, and 4) have been implicated to be involved in the pathogenesis of RA only in Japanese populations [7,9]. No such association of PADI4 variability with RA prevalence and severity could be demonstrated in various European populations [10-14]. In our study, also, an influence of PADI4 genotype on disease activity or anti-CCP level could not be demonstrated. The mechanism by which PADI4 variability may influence the break of tolerance is still unknown. Initially, it was argued that detectable differences in mRNA stability could result in higher enzymatic activity in cases where the susceptibility haplotypes (2,3 and 4) of PADI4 are present, leading to the generation of larger amounts of citrullinated peptides [7]. Most recently, a close association of the production of anti-CCP antibodies and HLA-DRB1 has been described [6,11,13,19], indicating the importance of antigen presentation in the induction of autoimmunity. This finding clearly could be confirmed in our study.
###end p 34
###begin p 35
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 196 202 196 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 304 306 304 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 326 337 326 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">haplotype 3</italic>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 358 360 358 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 368 391 368 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">padi4_94*T, padi4_104*C</italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 416 418 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 545 547 545 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 639 645 639 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 761 762 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
With the exception of haplotype 4, the frequencies of all other PADI4 haplotypes in our control individuals were comparable with those reported by other groups [7,9,10,14]. While the frequency of PADI4 haplotype 4 in our study (7.8%) was similar to that reported by groups from the United Kingdom (9.4%, P = 0.51; here termed haplotype 3) [10], Spain (5.9%, P = 0.32; padi4_94*T, padi4_104*C) [14], and Japan (5.5%, P = 0.17) [9], it was statistically significant different from the frequency reported by the large initial Japanese study (4.0%, P = 0.013) [7]. All of our patients and healthy individuals were Caucasian. The fact that the PADI4 haplotype 4 frequency in our control population was significantly higher compared with one of the Japanese studies [7] may therefore be influenced by differences in the ethnic background.
###end p 35
###begin p 36
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 291 297 291 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
In our study, a statistically significant positive association of PADI4 haplotype 4 with RA was observed (odds ratio = 2.0, 95% confidence interval = 1.1-3.8). The presence of this haplotype did not influence disease activity or the anti-CCP level. We did not found an association of RA and PADI4 haplotypes 2 and 3, which were described as the principal susceptibility haplotypes in the Japanese population [7]. However, we cannot exclude that this difference may be influenced by the size of our study population.
###end p 36
###begin p 37
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 215 221 209 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 332 338 320 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
When analysing the distributions of those PADI4 SNPs covered by our genotyping approach, padi4_89A-->G, padi4_90C-->T, and padi4_94C-->T were found to be significantly associated with RA. These SNPs are common with PADI4 haplotype 4 and haplotype 2/3, whereas padi4_104C-->T, padi4_95G-->C, and padi4_96T-->C, which are common with PADI4 haplotype 4 and haplotype 1, exhibited no association with RA.
###end p 37
###begin p 38
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
The present study identified uncommon PADI4 variants that are not typically included among the five main PADI4 haplotypes. Consistent with our previous findings in healthy individuals [8], this study also revealed additional variability in PADI4 exons 2-4 in RA patients. As a result of this study, the frequency of uncommon PADI4 variants as identified earlier [8] was apparently not different quantitatively or qualitatively between patients and controls.
###end p 38
###begin p 39
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
Of note, a statistically significant association between certain PADI4 genotypes and RA was detected in our study, in contrast to reports from other European groups [10-14]. This puzzling discrepancy may be due to influencing factors, such as a homogeneous Caucasian population, although we cannot definitely exclude other selection biases.
###end p 39
###begin p 40
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
The question of whether PADI4 variability alters the interactions between the enzyme and possible target proteins remains unclear [20]. Further studies are needed to characterise the influence of this variability on the repertoire of deiminated target proteins.
###end p 40
###begin title 41
Conclusion
###end title 41
###begin p 42
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 191 197 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 366 372 360 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
In summary, the PADI4 haplotype 4 and the SNPs padi4_89A-->G, padi4_90C-->T, and padi4_94C-->T were found to be significantly associated with RA in a German population. The genomic region of PADI4 exons 2-4 of RA patients exhibits additional variability, which is apparently not different quantitatively and qualitatively between RA patients and controls. While the PADI4 genotype did not influence disease activity or the anti-CCP level, the presence of the HLA-DRB1 shared epitope was associated with significantly higher anti-CCP levels.
###end p 42
###begin title 43
Abbreviations
###end title 43
###begin p 44
anti-CCP = anti-cyclic citrullinated peptide antibodies; PADI4 = peptidylarginine deiminase type 4; PCR = polymerase chain reaction; RA = rheumatoid arthritis; SNP = single nucleotide polymorphism.
###end p 44
###begin title 45
Competing interests
###end title 45
###begin p 46
The authors declare that they have no competing interests.
###end p 46
###begin title 47
Authors' contributions
###end title 47
###begin p 48
BH participated in the design and coordination of the study, carried out the molecular genetic and statistical analyses, and drafted the manuscript. TH, RG, HK, GRB, and AS participated in the coordination of the study and in drafting the manuscript. TD participated in the design and coordination of the study, and critically revised the manuscript. All authors read and approved the final manuscript.
###end p 48
###begin title 49
Acknowledgements
###end title 49
###begin p 50
The authors thank Gisela Diederich for excellent technical assistance.
###end p 50
###begin article-title 51
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 140 145 <span type="species:ncbi:9606">human</span>
Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6
###end article-title 51
###begin article-title 52
The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues
###end article-title 52
###begin article-title 53
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin
###end article-title 53
###begin article-title 54
Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule
###end article-title 54
###begin article-title 55
Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors
###end article-title 55
###begin article-title 56
Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis
###end article-title 56
###begin article-title 57
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis
###end article-title 57
###begin article-title 58
High variability of peptidylarginine deiminase 4 (PADI4) in a healthy white population: characterization of six new variants of PADI4 exons 2-4 by a novel haplotype-specific sequencing-based approach
###end article-title 58
###begin article-title 59
Association between PADI4 and rheumatoid arthritis: a replication study
###end article-title 59
###begin article-title 60
A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population
###end article-title 60
###begin article-title 61
Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis
###end article-title 61
###begin article-title 62
A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population
###end article-title 62
###begin article-title 63
Functional haplotypes of PADI4: relevance for rheumatoid arthritis-specific synovial intracellular citrullinated proteins and anti-citrullinated protein antibodies
###end article-title 63
###begin article-title 64
PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population
###end article-title 64
###begin article-title 65
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
###end article-title 65
###begin article-title 66
Identification and characterization of a novel HLA-DRB1 allele, DRB1*0830*
###end article-title 66
###begin article-title 67
Genetic epidemiology of rheumatoid arthritis
###end article-title 67
###begin article-title 68
Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis
###end article-title 68
###begin article-title 69
Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins
###end article-title 69
###begin article-title 70
###xml 50 55 <span type="species:ncbi:9606">human</span>
Structural basis for Ca(2+)-induced activation of human PAD4
###end article-title 70
###begin title 71
Figures and Tables
###end title 71
###begin p 72
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 127 133 127 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
Determination of PADI4 haplotype constellations by haplotype-specific long-range PCR. Eight genomic DNA samples with different PADI4 haplotype constellations were tested by haplotype-specific long-range PCR using primer mixes specific for padi4_89*A/padi4_96*T (haplotype 1), padi4_89*A/padi4_96*C (haplotype 1B), padi4_89*G/padi4_96*T (haplotype 4), and padi4_89*G/padi4_96*C (haplotype 2/3).
###end p 72
###begin p 73
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
PADI4 haplotype combinations in Caucasian individuals
###end p 73
###begin p 74
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 93 95 93 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 127 129 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 152 154 152 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Frequencies of different PADI4 haplotype combinations in patients with rheumatoid arthritis (n = 102) and in healthy controls (n = 102) are presented. *P < 0.05 (Fisher's exact test).
###end p 74
###begin p 75
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
PADI4 haplotype frequencies in Caucasian individuals
###end p 75
###begin p 76
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 79 81 79 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 113 115 113 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
PADI4 haplotype and carrier frequencies in patients with rheumatoid arthritis (n = 102) and in healthy controls (n = 102) are presented. Results of univariate analyses (odds ratio, 95% confidence interval) and Fisher's exact tests are indicated.
###end p 76
###begin p 77
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
Frequencies of PADI4 variants in Caucasian individuals
###end p 77
###begin p 78
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 80 82 80 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 114 116 114 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
The allele frequencies of PADI4 variants in patients with rheumatoid arthritis (n = 102) and in healthy controls (n = 102) are presented. Results of univariate analyses (odds ratio [95% confidence interval]) and Fisher's exact tests are indicated.
###end p 78

